Dubois-Stringfellow Nathalie has filed 24 insider transactions across 1 company since January 2024.
Most recent transaction: a grant/award of 800000 shares of SANGAMO THERAPEUTICS, INC ($SGMO) on April 01, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 800000 | $0.00 | 800,000.0000 | 336,494,489 | 9999.99% | 0.24% |
| Feb. 25, 2026 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 12354 | $0.47 | 678,711.0000 | 336,494,489 | 1.79% | 0.00% |
| Feb. 24, 2026 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 2063 | $0.47 | 691,065.0000 | 336,494,489 | 0.30% | 0.00% |
| Jan. 22, 2026 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 36676 | $0.40 | 693,128.0000 | 336,494,489 | 5.03% | 0.01% |
| Nov. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 2544 | $0.42 | 719,804.0000 | 336,494,489 | 0.35% | 0.00% |
| Oct. 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 43741 | $0.66 | 722,348.0000 | 224,710,019 | 5.71% | 0.02% |
| Aug. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1792 | $0.59 | 766,089.0000 | 224,710,019 | 0.23% | 0.00% |
| July 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 31866 | $0.48 | 767,881.0000 | 224,710,019 | 3.98% | 0.01% |
| May 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1792 | $0.47 | 799,747.0000 | 224,710,019 | 0.22% | 0.00% |
| April 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 31866 | $0.78 | 801,539.0000 | 224,710,019 | 3.82% | 0.01% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 560000 | $0.00 | 560,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1792 | $1.00 | 714,918.0000 | 0 | 0.25% | 0.00% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1513 | $0.96 | 713,405.0000 | 0 | 0.21% | 0.00% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | A | Common Stock | 120000 | $0.00 | 833,405.0000 | 0 | 16.82% | 0.00% |
| Jan. 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 129593 | $1.15 | 716,710.0000 | 0 | 15.31% | 0.00% |
| Nov. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1787 | $1.88 | 842,811.0000 | 0 | 0.21% | 0.00% |
| Nov. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1508 | $1.94 | 841,303.0000 | 0 | 0.18% | 0.00% |
| Aug. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1508 | $0.86 | 844,598.0000 | 0 | 0.18% | 0.00% |
| Aug. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1787 | $0.86 | 846,106.0000 | 0 | 0.21% | 0.00% |
| May 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1508 | $0.60 | 842,893.0000 | 0 | 0.18% | 0.00% |
| May 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 1787 | $0.60 | 844,401.0000 | 0 | 0.21% | 0.00% |
| Feb. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 5010 | $1.13 | 846,188.0000 | 0 | 0.59% | 0.00% |
| Feb. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F | Common Stock | 5474 | $1.13 | 851,198.0000 | 0 | 0.64% | 0.00% |
| Jan. 22, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | A | Common Stock | 712500 | $0.00 | 856,672.0000 | 0 | 494.20% | 0.00% |